NYSE:EBS Emergent Biosolutions Q3 2024 Earnings Results & Report $6.90 -0.02 (-0.22%) Closing price 10/14/2026 03:59 PM EasternExtended Trading$6.85 -0.04 (-0.65%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Emergent Biosolutions reported Q3 2024 earnings on January 15, 2025. The company reported EPS of $1.37, while revenue was $10.00 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateJanuary 15, 2025TimeBefore Market Opens Emergent Biosolutions EPS ResultsActual EPS$1.37Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersEmergent Biosolutions Revenue ResultsActual Revenue$10.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsEmergent Biosolutions' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, October 28, 2026 at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Emergent Biosolutions Q3 2024 Earnings FAQ Did Emergent Biosolutions beat earnings estimates for Q3 2024? Emergent Biosolutions (NYSE:EBS) reported earnings of $1.37 per share for Q3 2024. The report was announced on Wednesday, January 15, 2025. What was Emergent Biosolutions' revenue for Q3 2024? Emergent Biosolutions reported revenue of $10.00 million for Q3 2024. When is Emergent Biosolutions' next earnings date? Emergent Biosolutions' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Emergent Biosolutions on the company's earnings history page. Emergent Biosolutions Earnings HeadlinesComparing Sutro Biopharma (NASDAQ:STRO) & Emergent Biosolutions (NYSE:EBS)October 11, 2026 | americanbankingnews.comInsider Selling: Emergent Biosolutions (NYSE:EBS) SVP Sells $19,590.00 in StockOctober 5, 2026 | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Average Target Price of $10.00October 5, 2026 | americanbankingnews.comContrasting Immatics (NASDAQ:IMTX) and Emergent Biosolutions (NYSE:EBS)October 4, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSSeptember 24, 2026 | prnewswire.comSee More Emergent Biosolutions Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Emergent Biosolutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Emergent Biosolutions and other key companies, straight to your email. Email Address About Emergent BiosolutionsEmergent Biosolutions (NYSE:EBS) (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers. Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin. The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology organizations. Founded in 1998, Emergent is headquartered in Gaithersburg, Maryland. Its operations and customer relationships have included the United States and international markets, with a significant portion of its business tied to government preparedness programs. Joseph C. Papa serves as the company’s chief executive officer.View Emergent Biosolutions ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
